HbA1c Testing Device Market Size, Share, Growth, and Industry Analysis, By Type (Point-of-care (POC) Testing Devices,Laboratory-based Testing Devices), By Application (Hospital,Homecare,Other), Regional Insights and Forecast to 2035

HbA1c Testing Device Market Overview

The global HbA1c Testing Device Market size is projected to grow from USD 158.1 million in 2026 to USD 172.19 million in 2027, reaching USD 340.79 million by 2035, expanding at a CAGR of 8.91% during the forecast period.

The HbA1c testing device market is witnessing rapid expansion due to the increasing prevalence of diabetes worldwide, which affects more than 537 million adults as of 2021, with projections reaching 643 million by 2030. The adoption of HbA1c testing is fueled by the fact that approximately 79% of diabetic adults live in low- and middle-income countries, where the demand for accessible testing devices is surging. More than 1.5 million deaths annually are linked to diabetes-related complications, creating strong demand for reliable HbA1c analyzers and point-of-care devices. Clinical adoption is accelerating as over 60% of healthcare facilities globally integrate HbA1c monitoring.

The USA accounts for a significant portion of the HbA1c testing device market, driven by its high diabetic population, estimated at 37.3 million in 2022, which represents 11.3% of the country’s total population. Around 96 million adults in the USA are in the prediabetes stage, highlighting the large demand for diagnostic testing. More than 85% of healthcare providers in the USA adopt HbA1c testing for monitoring long-term glucose levels, supported by national guidelines. With an estimated 1.4 million new diabetes cases diagnosed annually, the USA demonstrates strong demand for HbA1c testing devices in hospitals, clinics, and homecare settings.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Driver: 65% of healthcare providers highlight early diabetes detection as the leading driver for HbA1c testing device adoption.
• Major Market Restraint: 48% of end-users identify high device costs as the primary restraint limiting adoption across low-income regions.
• Emerging Trends: 52% of hospitals are shifting toward point-of-care HbA1c testing devices for faster patient management.
• Regional Leadership: North America holds 41% of the global HbA1c testing device market share due to advanced healthcare infrastructure.
• Competitive Landscape: 37% of global device sales are controlled by the top three manufacturers, showing strong market consolidation.
• Market Segmentation: 54% of testing is conducted in hospitals, while 28% comes from homecare settings and 18% from diagnostic labs.
• Recent Development: 43% of manufacturers have launched compact HbA1c testing devices with integrated connectivity since 2023.

HbA1c Testing Device Market Trends

The HbA1c testing device market is undergoing significant transformation, influenced by innovations in technology, patient demand, and clinical practices. Globally, more than 75% of hospitals are incorporating point-of-care HbA1c testing systems, reducing turnaround times from 24 hours to less than 15 minutes. Portable HbA1c analyzers are being adopted by approximately 40% of outpatient clinics, highlighting a strong movement toward decentralized testing. Digital integration is another critical trend, with nearly 58% of newly launched HbA1c testing devices offering Bluetooth or cloud-based connectivity for streamlined reporting.

Additionally, rising health awareness is pushing self-monitoring practices, with 31% of diabetic patients showing preference for home-based HbA1c test kits in 2024. Laboratories continue to account for 46% of test volumes, but hospitals are increasingly focusing on compact devices to support high patient inflows. Personalized diabetes management is also shaping demand, with over 62% of endocrinologists recommending routine HbA1c testing every three months for chronic diabetes patients. The market is also seeing geographic diversification, as 49% of new device sales come from Asia-Pacific and Latin America, regions experiencing sharp increases in diabetes incidence. Together, these market trends are driving a more patient-centric, technologically advanced HbA1c testing landscape.

HbA1c Testing Device Market Dynamics

DRIVER

"Increasing global diabetes prevalence."

The growing number of diabetic patients worldwide is the primary driver of HbA1c testing device adoption. The International Diabetes Federation estimates that 537 million adults live with diabetes as of 2021, projected to reach 643 million by 2030 and 783 million by 2045. In the USA alone, 1.4 million new cases are diagnosed each year, representing a strong demand base for HbA1c monitoring. More than 80% of clinicians rely on HbA1c testing for treatment adjustments, demonstrating its clinical significance. With 90% of diabetes cases categorized as type 2, where long-term monitoring is essential, the demand for HbA1c testing devices continues to grow.

RESTRAINT

"High device and consumable costs."

Despite growth opportunities, affordability remains a critical barrier. Approximately 48% of healthcare facilities in low-income countries report limited access to HbA1c testing devices due to high procurement and maintenance costs. Consumables such as test cartridges add recurring expenses, representing up to 35% of the total testing cost per patient. Rural healthcare centers, which serve 55% of diabetic patients in developing nations, often lack adequate funding to acquire modern analyzers. As a result, adoption rates remain lower in regions where per capita healthcare expenditure is below USD 1000 annually, directly restraining widespread market penetration.

OPPORTUNITY

"Expansion of point-of-care and home-based testing."

The rise of decentralized care creates strong growth opportunities for HbA1c testing device manufacturers. Around 31% of diabetic patients are already adopting home-based HbA1c kits, reflecting a significant shift in patient behavior. In rural Asia and Africa, mobile health clinics are introducing portable HbA1c analyzers, expanding access to more than 120 million underserved patients. Hospital procurement departments are prioritizing compact, digitally connected devices, with 43% of new contracts emphasizing connectivity features. The growing adoption of preventive health check-ups, covering 46% of urban adult populations in Asia-Pacific, further enhances the demand for rapid and accessible HbA1c testing.

CHALLENGE

"Quality control and regulatory compliance."

Ensuring test accuracy and meeting international regulatory standards is one of the biggest challenges for device manufacturers. Approximately 27% of small and mid-sized laboratories report inconsistencies in HbA1c readings due to lack of calibration, which impacts patient outcomes. Regulatory approvals are also becoming more stringent, with over 64% of manufacturers facing delays in product launches because of compliance testing. In emerging markets, where 55% of healthcare centers lack standardized quality protocols, inaccurate readings remain a concern. This challenge underscores the importance of robust R&D investment and adherence to quality assurance standards to ensure device reliability across all regions.

HbA1c Testing Device Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Point-of-Care (POC) Testing Devices: are gaining traction due to their speed and accessibility. Over 52% of outpatient clinics have adopted portable HbA1c analyzers to manage patient loads efficiently. These devices provide results in under 10 minutes compared to laboratory systems that may take up to 24 hours.

The Point-of-Care HbA1c Testing Devices segment is estimated to hold USD 86.72 million in 2025, expanding to USD 187.45 million by 2034, advancing at a steady CAGR of 8.92% across healthcare applications.

Top 5 Major Dominant Countries in the Point-of-Care Segment

• United States: Estimated at USD 28.34 million in 2025, projected to reach USD 61.23 million by 2034, with a CAGR of 8.95%, holding the largest market share in POC HbA1c testing.
• Germany: Valued at USD 9.41 million in 2025, growing to USD 20.13 million by 2034, with a CAGR of 8.90%, leading Europe’s demand for advanced diabetes POC diagnostics.
• China: Standing at USD 7.86 million in 2025, increasing to USD 16.85 million by 2034, with a CAGR of 8.93%, supported by rising diabetes cases and adoption of POC devices.
• India: Estimated at USD 6.72 million in 2025, projected to hit USD 14.38 million by 2034, recording a CAGR of 8.97%, driven by rising awareness in primary healthcare centers.
• Japan: Valued at USD 5.93 million in 2025, forecasted to reach USD 12.70 million by 2034, at a CAGR of 8.88%, reflecting strong uptake of quick testing kits in clinics.

Laboratory-Based Testing Devices: analyzers remain the backbone of large-scale testing due to their accuracy and ability to handle high volumes. Laboratories process more than 53% of HbA1c tests globally, with some high-capacity analyzers capable of running over 200 samples per day.

The Laboratory-based HbA1c Testing Devices segment is valued at USD 58.45 million in 2025, expected to climb to USD 125.46 million by 2034, progressing at a CAGR of 8.90%, supported by hospital and diagnostic use.

Top 5 Major Dominant Countries in the Laboratory-based Segment

• United States: Holding USD 19.65 million in 2025, reaching USD 42.16 million by 2034, with a CAGR of 8.91%, maintaining dominance in hospital-based HbA1c laboratory diagnostics.
• United Kingdom: Valued at USD 7.38 million in 2025, projected to reach USD 15.82 million by 2034, growing at a CAGR of 8.89%, with strong NHS adoption of lab analyzers.
• China: Estimated at USD 6.14 million in 2025, expanding to USD 13.16 million by 2034, showing a CAGR of 8.92%, reflecting high investment in diagnostic infrastructure.
• Germany: Standing at USD 5.87 million in 2025, set to grow to USD 12.56 million by 2034, achieving a CAGR of 8.87%, representing Europe’s second-largest lab-based HbA1c market.
• Japan: Valued at USD 4.76 million in 2025, increasing to USD 10.18 million by 2034, with a CAGR of 8.90%, supported by advanced healthcare infrastructure and strong clinical accuracy standards.

BY APPLICATION

Hospitals: represent the largest application segment, accounting for 54% of HbA1c device utilization in 2024. Approximately 78% of multi-specialty hospitals globally conduct routine HbA1c monitoring for diabetes management.

The hospital application segment is valued at USD 68.56 million in 2025, expanding to USD 147.04 million by 2034, advancing at a CAGR of 8.91%, supported by demand for centralized testing in healthcare facilities.

Top 5 Major Dominant Countries in the Hospital Segment

• United States: Holding USD 23.67 million in 2025, projected to hit USD 50.83 million by 2034, with a CAGR of 8.93%, driven by high inpatient and outpatient diabetes testing volumes.
• China: Valued at USD 9.12 million in 2025, rising to USD 19.59 million by 2034, with a CAGR of 8.92%, reflecting rapid hospital expansion in urban regions.
• India: Estimated at USD 7.86 million in 2025, increasing to USD 16.86 million by 2034, growing at a CAGR of 8.95%, supported by government-led hospital modernization.
• Germany: Standing at USD 6.78 million in 2025, expected to reach USD 14.56 million by 2034, at a CAGR of 8.90%, reflecting Europe’s structured diabetes care infrastructure.
• Japan: Valued at USD 5.64 million in 2025, forecasted to reach USD 12.12 million by 2034, with a CAGR of 8.89%, supported by strong hospital-based diagnostic culture.

Homecare: segment is emerging as a significant contributor, with 28% of market share in 2024. Approximately 31% of diabetic patients prefer self-monitoring using home HbA1c kits for convenience and reduced hospital visits. In Europe, where more than 33 million people live with diabetes, home-based kits are widely distributed through pharmacies and retail channels.

The homecare application segment is valued at USD 46.12 million in 2025, projected to grow to USD 98.89 million by 2034, recording a CAGR of 8.92%, reflecting the rise of self-testing and patient monitoring.

Top 5 Major Dominant Countries in the Homecare Segment

• United States: Holding USD 15.21 million in 2025, reaching USD 32.62 million by 2034, growing at a CAGR of 8.94%, reflecting widespread adoption of self-monitoring HbA1c devices.
• China: Valued at USD 7.24 million in 2025, projected to hit USD 15.53 million by 2034, advancing at a CAGR of 8.92%, supported by increased health awareness and rural outreach.
• India: Standing at USD 6.32 million in 2025, increasing to USD 13.55 million by 2034, recording a CAGR of 8.97%, reflecting strong demand for affordable homecare devices.
• Germany: Estimated at USD 5.47 million in 2025, growing to USD 11.71 million by 2034, at a CAGR of 8.88%, supported by aging population home testing needs.
• Japan: Valued at USD 4.83 million in 2025, projected to reach USD 10.31 million by 2034, showing a CAGR of 8.90%, driven by elderly diabetic patient self-testing adoption.

Other Diagnostic Facilities: including specialized clinics and independent laboratories, contribute 18% of the HbA1c testing device market. Around 45% of private diagnostic labs across Asia-Pacific now offer HbA1c testing as part of their preventive health packages.

The “Other” applications segment is estimated at USD 30.49 million in 2025, expected to expand to USD 66.98 million by 2034, at a CAGR of 8.90%, covering clinics, diagnostic centers, and research institutions.

Top 5 Major Dominant Countries in the Other Applications Segment

• United States: Valued at USD 10.18 million in 2025, projected to reach USD 22.35 million by 2034, at a CAGR of 8.91%, covering diagnostic centers and research institutes.
• Germany: Standing at USD 4.56 million in 2025, forecasted to hit USD 10.02 million by 2034, with a CAGR of 8.89%, supported by advanced lab network presence.
• China: Estimated at USD 4.21 million in 2025, rising to USD 9.25 million by 2034, recording a CAGR of 8.92%, driven by diagnostic expansion in urban areas.
• India: Holding USD 3.47 million in 2025, increasing to USD 7.62 million by 2034, advancing at a CAGR of 8.95%, reflecting fast-growing clinic-based HbA1c demand.
• United Kingdom: Valued at USD 3.12 million in 2025, projected to hit USD 6.85 million by 2034, with a CAGR of 8.87%, representing strong outpatient diagnostic testing.

HbA1c Testing Device Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

dominates the HbA1c testing device market with a 41% share in 2024, supported by its advanced healthcare infrastructure and high diabetes prevalence. The USA alone accounts for 37.3 million diabetic patients, representing 11.3% of its total population. Canada adds 3.6 million patients, bringing regional demand to over 40 million individuals requiring regular HbA1c monitoring.

The North America HbA1c Testing Device Market is valued at USD 52.27 million in 2025, expected to expand to USD 112.16 million by 2034, recording a CAGR of 8.92%, with the U.S. leading adoption across hospitals and homecare.

North America – Major Dominant Countries

• United States: USD 43.52 million in 2025, rising to USD 93.40 million by 2034, with a CAGR of 8.93%, leading in POC and lab-based HbA1c testing.
• Canada: USD 4.61 million in 2025, projected to reach USD 9.91 million by 2034, with a CAGR of 8.91%, reflecting strong healthcare investments.
• Mexico: USD 2.37 million in 2025, expanding to USD 5.09 million by 2034, with a CAGR of 8.92%, supported by rising diabetes prevalence.
• Cuba: USD 0.91 million in 2025, reaching USD 1.97 million by 2034, CAGR of 8.90%, reflecting expanding diagnostic services.
• Puerto Rico: USD 0.86 million in 2025, increasing to USD 1.79 million by 2034, CAGR of 8.88%, with growing HbA1c adoption in hospitals.

EUROPE

holds 28% of the global HbA1c testing device market share in 2024, reflecting its well-established healthcare systems and strong adoption of laboratory-based analyzers. The region has over 61 million people living with diabetes, representing 9% of the adult population, with Germany, the UK, France, and Italy being key contributors. Approximately 72% of European hospitals rely on laboratory HbA1c analyzers due to their high precision, while 43% of outpatient clinics have shifted toward point-of-care systems to reduce turnaround time.

The Europe HbA1c Testing Device Market is valued at USD 42.13 million in 2025, expected to rise to USD 90.34 million by 2034, showing a CAGR of 8.91%, driven by structured healthcare systems and diabetes management programs.

Europe – Major Dominant Countries

• Germany: USD 11.28 million in 2025, increasing to USD 24.19 million by 2034, CAGR of 8.89%, holding the largest share in Europe.
• United Kingdom: USD 8.76 million in 2025, growing to USD 18.78 million by 2034, CAGR of 8.90%, with NHS adoption supporting demand.
• France: USD 7.31 million in 2025, projected to hit USD 15.68 million by 2034CAGR of 8.88%, representing strong hospital networks.
• Italy: USD 6.09 million in 2025, reaching USD 13.07 million by 2034, CAGR of 8.92%, reflecting demand for homecare HbA1c devices.
• Spain: USD 4.69 million in 2025, climbing to USD 9.96 million by 2034, CAGR of 8.87%, supported by growing diabetes cases.

ASIA-PACIFIC

represents 22% of the global HbA1c testing device market in 2024, driven by its rapidly growing diabetic population, estimated at 206 million adults. China alone has over 141 million diabetes cases, while India accounts for 77 million, making these two countries central to regional demand. Approximately 59% of testing in Asia-Pacific is conducted in hospitals, while independent diagnostic labs manage 27% of test volumes, supported by a large urban population seeking preventive healthcare packages.

The Asia HbA1c Testing Device Market is valued at USD 36.29 million in 2025, projected to reach USD 77.73 million by 2034, growing at a CAGR of 8.93%, led by China, India, and Japan.

Asia – Major Dominant Countries

• China: USD 12.45 million in 2025, forecasted to reach USD 26.69 million by 2034, CAGR of 8.92%, leading Asia’s market share.
• India: USD 10.86 million in 2025, projected to rise to USD 23.25 million by 2034, CAGR of 8.95%, supported by healthcare reforms.
• Japan: USD 7.89 million in 2025, climbing to USD 16.89 million by 2034, CAGR of 8.90%, with strong hospital-based demand.
• South Korea: USD 3.13 million in 2025, expanding to USD 6.72 million by 2034, CAGR of 8.89%, driven by diagnostic innovations.
• Australia: USD 2.76 million in 2025, reaching USD 5.87 million by 2034, CAGR of 8.91%, with growing homecare segment.

MIDDLE EAST & AFRICA

account for 9% of the global HbA1c testing device market share in 2024, but the region shows some of the fastest adoption rates due to rising diabetes prevalence. Around 24 million adults live with diabetes in this region, with 73% of cases concentrated in urban centers. Gulf Cooperation Council (GCC) countries such as Saudi Arabia, the UAE, and Qatar exhibit some of the highest diabetes rates globally, with prevalence levels reaching 18–20% of the adult population. This creates strong demand for regular HbA1c monitoring in hospitals and specialized clinics.

The Middle East and Africa HbA1c Testing Device Market is valued at USD 14.48 million in 2025, increasing to USD 32.68 million by 2034, recording a CAGR of 8.90%, driven by rising diabetes prevalence and healthcare expansion.

Middle East and Africa – Major Dominant Countries

• Saudi Arabia: USD 4.21 million in 2025, projected to hit USD 9.51 million by 2034, CAGR of 8.92%, leading regional demand.
• United Arab Emirates: USD 2.96 million in 2025, growing to USD 6.66 million by 2034, CAGR of 8.91%, with strong private healthcare adoption.
• South Africa: USD 2.37 million in 2025, increasing to USD 5.23 million by 2034, CAGR of 8.89%, reflecting growing diabetes care centers.
• Egypt: USD 2.04 million in 2025, forecasted to reach USD 4.49 million by 2034, CAGR of 8.87%, supported by healthcare modernization.
• Nigeria: USD 1.64 million in 2025, expanding to USD 3.79 million by 2034, CAGR of 8.95%, showing rising adoption of diagnostic testing.

List of Top HbA1c Testing Device Companies

• HUMAN
• Trinity Biotech
• Ceragem Medisys Inc
• Abbott
• SEKISUI MEDICAL CO., LTD.
• SAKAE CO. LTD.
• Hoffmann-La Roche Ltd
• Bio-Rad Laboratories, Inc.
• Menarini Diagnostics s.r.l
• Siemens Healthineers AG

Abbott controls approximately 12% of the global HbA1c testing device market share in 2024, driven by its wide adoption of point-of-care systems in North America and Asia.

Hoffmann-La Roche Ltd holds nearly 11% market share globally, with strong dominance in Europe where its laboratory-based analyzers account for 39% of hospital installations.

Investment Analysis and Opportunities

Investment activity in the HbA1c testing device market has intensified as healthcare providers and manufacturers respond to increasing global diabetes prevalence. In 2023–2024, more than 1.2 billion USD in private equity and venture capital was directed toward diagnostic device companies focusing on point-of-care HbA1c testing. Approximately 47% of these investments targeted Asia-Pacific startups developing portable analyzers to serve large urban and rural populations. Hospitals and diagnostic labs represent a major investment channel, with 56% of procurement budgets in North America and Europe allocated to diagnostic devices, including HbA1c analyzers.

Strategic partnerships between manufacturers and healthcare networks are expanding, with 32% of device companies entering long-term supply contracts with large hospital chains. Government support also drives opportunities, as 41% of diabetes-focused public health initiatives across Asia and Africa now include HbA1c testing as a key component. Investors are also eyeing homecare opportunities, as 28% of diabetic patients globally show preference for self-monitoring kits. This shift has led to 19% growth in direct-to-consumer device distribution channels in 2024 alone.

New Product Development

The HbA1c testing device market is experiencing a surge in new product development, with manufacturers focusing on speed, portability, and digital integration. Between 2023 and 2024, nearly 43% of newly launched HbA1c devices featured Bluetooth or Wi-Fi connectivity to allow seamless data transfer into electronic health records. Compact analyzers capable of delivering results in under 5 minutes are now used by 34% of outpatient clinics, reducing patient waiting times dramatically. Manufacturers are also focusing on miniaturization, with 27% of new HbA1c analyzers designed specifically for homecare usage. These kits use finger-prick blood samples of less than 5 microliters, a significant reduction compared to traditional laboratory devices requiring 50–100 microliters.

Cloud-enabled devices are expanding rapidly, with 39% of newly launched systems allowing remote monitoring by healthcare providers. Customization is another focus area, as 31% of new systems integrate multi-test panels that combine HbA1c testing with lipid and glucose monitoring. This approach supports comprehensive diabetes care in a single device. Sustainability is emerging as well, with 22% of manufacturers introducing recyclable test cartridges to reduce clinical waste. These advancements underline the industry’s strong emphasis on patient convenience, clinical accuracy, and cost-effective HbA1c testing solutions for diverse healthcare settings.

Five Recent Developments

• Abbott introduced a next-generation handheld HbA1c analyzer in 2024, offering results in 3.5 minutes with connectivity to cloud-based patient portals.
• Siemens Healthineers expanded its product line in 2023 with a high-throughput HbA1c laboratory system capable of processing 250 samples per hour.
• Bio-Rad Laboratories launched an AI-driven calibration technology in 2024, improving test accuracy by 18% in clinical environments.
• Roche announced in 2025 the integration of HbA1c testing into its existing diagnostic platforms, allowing combined testing with glucose and lipid panels.
• Trinity Biotech introduced a low-cost HbA1c kit in 2023, specifically targeting rural healthcare centers in Asia and Africa, reducing per-test costs by 27%.

Report Coverage of HbA1c Testing Device Market

The HbA1c Testing Device Market Report provides a comprehensive analysis of industry performance, covering market size, share, segmentation, and regional outlook across 2023–2034. The scope includes both point-of-care devices and laboratory-based analyzers, with detailed insights into applications across hospitals, homecare, and diagnostic laboratories. More than 10 leading companies, including Abbott, Roche, Siemens Healthineers, and Bio-Rad Laboratories, are assessed in terms of competitive landscape, product offerings, and innovation strategies.

The report also examines market dynamics in depth, highlighting key drivers such as rising diabetes prevalence, restraints like high device costs, opportunities in decentralized testing, and challenges related to regulatory compliance. Regional coverage spans North America, Europe, Asia-Pacific, and Middle East & Africa, representing over 537 million diabetes patients globally in 2021, projected to rise to 643 million by 2030.

HbA1c Testing Device Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 158.1 Million in 2026
Market Size Value By	USD 340.79 Million by 2035
Growth Rate	CAGR of 8.91% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Point-of-care (POC) Testing Devices Laboratory-based Testing Devices By Application : Hospital Homecare Other
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample